Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Schizophr Relat Psychoses. 2015 Jan;8(4):196-200. doi: 10.3371/CSRP.RAPA.030113.

An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes.

Author information

1
Department of Psychiatry, Yale University School of Medicine, New Haven, CT.

Abstract

A possible mechanism of antipsychotic-induced weight gain is activation of hypothalamic monophosphate-dependent kinase (AMPK) mediated by histamine 1 receptors. Alpha-lipoic acid (ALA), a potent antioxidant, counteracts this effect and may be helpful in reducing weight for patients taking antipsychotics. The objective of this open-label study was to assess the efficacy of ALA (1,200 mg) on twelve non-diabetic schizophrenia patients over ten weeks. Participants lost significant weight during the intervention (-2.2 kg±2.5 kg). ALA was well tolerated and was particularly effective for individuals taking strongly antihistaminic antipsychotics (-2.9 kg±2.6 kg vs. -0.5 kg±1.0 kg).

CLINICAL TRIAL REGISTRATION:

NCT01355952.

KEYWORDS:

Alpha-Lipoic Acid; Obesity; Schizoaffective Disorder; Schizophrenia

PMID:
23471087
DOI:
10.3371/CSRP.RAPA.030113
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Allen Press, Inc.
    Loading ...
    Support Center